Mr. Scott Spearn reports

MEDX HEALTH ANNOUNCES THAT DR. EGGERT STOCKFLETH, DIRECTOR OF THE UNIVERSITY DEPARTMENT OF DERMATOLOGY AT ST. JOSEF-HOSPITAL IN BOCHUM, GERMANY HAS JOINED ITS MEDICAL ADVISORY BOARD

Dr. Eggert Stockfleth, director of the university department of dermatology at St. Josef-Hospital in Bochum, Germany, has agreed to join MedX Health Corp.'s medical advisory board. Dr. Stockfleth was previously the director of the Skin Cancer Center in Berlin.

"The addition of Dr. Stockfleth to our medical advisory board completes our group of highly accomplished physicians from around the world. They are respected thought leaders located in our targeted markets. We are very fortunate to have access to Dr. Stockfleth's knowledge and expertise," said Scott Spearn, chief executive officer of MedX.

"MedX's non-invasive skin cancer scanning technology is groundbreaking and I am honoured to be a member of such an esteemed group of physicians," Dr. Stockfleth said. "I see first-hand how MedX's technology is a game changer in early detection of skin cancers," he added. He noted that his clinic in Bochum receives in excess of 800 calls per day with respect to dermatological issues and has a capacity to handle only about half of the inquiries.

Dr. Stockfleth's research on dermatology, oncology and, in particular, skin cancer has been extensively published in peer-reviewed journals. He has contributed to the Journal of Infectious Diseases, the International Journal of Cancer, the Journal of Investigative Dermatology and The Lancet. He is also the former European president of Skin Care in Organ Transplant Patients Network (SCOPE). In 2008, he was one of the founders of the European Skin Cancer Foundation, which assists in developing and providing standardized treatments on a European level. Dr. Stockfleth graduated from the University of Hamburg and is a Jung-Foundation scholar.

About MedX Health Corp.

MedX, headquartered in Mississauga, Ont., is a leading medical device and software company focused on skin cancer with its DermSecure telemedicine platform, utilizing its SIAscopy technology.

We seek Safe Harbor.